Repeated rebiopsy for detection of EGFR T790M mutation in patients with advanced-stage lung adenocarcinoma: Associated factors and treatment outcomes of Osimertinib
Repeated rebiopsy for T790M detection in patients with NSCLC can increase the detection rate of the mutation. Detection of T790M by plasma ctDNA might be related to poor survival outcomes.
Authors
- Kyungjong Lee (ORCID: https://orcid.org/0000-0002-1642-8111)
- Sun Hye Shin (ORCID: https://orcid.org/0000-0003-3164-889X)
- Byeong‐Ho Jeong (ORCID: https://orcid.org/0000-0002-3124-1718)
- Junsu Choe (ORCID: https://orcid.org/0000-0003-3233-450X)
- Se‐Hoon Lee (ORCID: https://orcid.org/0000-0002-9219-3350)
- Sang‐Won Um (ORCID: https://orcid.org/0000-0002-9765-9068)
- Taeyun Kim (ORCID: https://orcid.org/0000-0001-7786-5051)
- Hojoong Kim (ORCID: https://orcid.org/0000-0001-9207-0433)
Institutions
- Kosin University Gospel Hospital (KR)
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1371/journal.pone.0310079
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea